145.49 0.00 (0.00%)
After hours: 5:00PM EDT
Previous close | 148.01 |
Open | 150.02 |
Bid | 143.00 x 100 |
Ask | 146.98 x 100 |
Day's range | 142.15 - 151.65 |
52-week range | 59.57 - 195.97 |
Volume | 613,446 |
Avg. volume | 570,164 |
Market cap | 6.66B |
Beta | 3.74 |
PE ratio (TTM) | N/A |
EPS (TTM) | -7.09 |
Earnings date | 7 Aug 2017 - 11 Aug 2017 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 206.29 |
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, an intravenous formulation of brexanolone (SAGE-547), for the treatment of postpartum depression (PPD). Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates intended to treat serious conditions, including increased interaction and guidance from the FDA.
Learn which stock fell on fears about merger and acquisition prospects.
Sage Therapeutics a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that data from clinical studies of its proprietary i.v.
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on April 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 162,000 shares of its common stock to twenty new employees under Sage’s 2016 Inducement Equity ...
Sage Therapeutics has to balance two competing interests when it comes to pricing its postpartum depression drug, CEO Jeff Jonas says.
Martin Shkreli's actions involving pharmaceutical pricing have had a long-lasting impact.
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
The biopharma's slide continues -- for good reason this time.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Sage will participate in a fireside chat presentation at the Cowen & Co.
Sage Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced ...
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, February 22, 2018 at 8:00 A.M.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Sage will participate in a fireside chat presentation at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 1:30 P.M.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the pricing of an underwritten public offering of 3,506,098 shares of its common stock at a public offering price of $164.00 per share.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that it has commenced an underwritten public offering of $575.0 million of its common stock.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the U.S.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on February 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 113,000 shares of its common stock to sixteen new employees under Sage’s 2016 Inducement Equity ...
Sage popped to a record high Wednesday after its depression drug also showed promise in an insomnia trial.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results from a Phase 1/2, double-blind, placebo-controlled study of SAGE-217 in the treatment of healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.
These small biotechs could be prime buyout candidates in 2018.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that in a corporate presentation at the 36th Annual J.P.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on January 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 144,800 shares of its common stock to fifteen new employees under Sage’s 2016 Inducement Equity ...
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company is scheduled to present at the J.P.